Citi Pharma Limited

CPHL

PK0126201018

Pharmaceuticals

End-of-day quote Pakistan S.E. Other stock markets 03:30:00 14/06/2024 am IST			5-day change	1st Jan Change
28.66 ^PKR	-1.55%		-1.17%	+20.72%

30/04	Citi Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI
2023	Citi Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI

Citi Pharma Limited has completed an IPO in the amount of PKR 2.326144 billion.

July 08, 2021 at 09:30 am IST

Citi Pharma Limited has completed an IPO in the amount of PKR 2.326144 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 72,692,000 PriceRange: PKR 32 Discount Per Security: PKR 0.48

Latest news about Citi Pharma Limited

Citi Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	30/04	CI
Citi Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023	06/23/06	CI
33,749,997 Ordinary Shares of Citi Pharma Limited are subject to a Lock-Up Agreement Ending on 24-JUN-2023.	24/23/24	CI
Citi Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	28/23/28	CI
Citi Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	01/23/01	CI
Citi Pharma Limited Reports Earnings Results for the First Quarter Ended September 30, 2022	18/22/18	CI
Citi Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2022	11/22/11	CI
Citi Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	23/22/23	CI
33,749,997 Ordinary Shares of Citi Pharma Limited are subject to a Lock-Up Agreement Ending on 24-JUN-2022.	24/22/24	CI
Citi Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	03/22/03	CI
Citi Pharma Limited Announces Earnings Results for the Year Ended June 30, 2021	30/21/30	CI
Citi Pharma Limited Announces Final Cash Dividend for the Year Ended June 30, 2021	30/21/30	CI
Citi Pharma Ltd. Announces Board Changes	06/21/06	CI
Citi Pharma Limited has completed an IPO in the amount of PKR 2.326144 billion.	08/21/08	CI
Citi Pharma Limited has filed an IPO in the amount of PKR 2.849526 billion.	12/21/12	CI

Chart Citi Pharma Limited

Duration

Period

More charts

Company Profile

Citi Pharma Limited is a Pakistan-based pharmaceutical company. The principal activity of the Company is manufacturing and sale of pharmaceuticals, medical chemicals, and botanical products. The Company's departments include API, formulation, and research and development. Its key products under the API segment include Paracetamol, Amoxicillin, Levofloxacin, Cefixime, Ciprofloxacin, Cephradine, Norfloxacin, Aspirin, Ibuprofen, and Ascorbic acid. The Company's formulation department produces tablets, liquids, and capsules. Its research and development activities deal with various forms ranging from the development of new chemical/drug entities to the evaluation of existing products for alternative indications. Its other products include Amlodopine, Nimesulide, Mefenamic Acid, Simvastatin, Ranitiddine as Hcl, and Levofloxicen(as Hemihydrate), among others.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

28.66

Average target price

Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CITI PHARMA LIMITED	+20.72%	2.35Cr
ELI LILLY AND COMPANY	+50.70%	79TCr
NOVO NORDISK A/S	+41.96%	63TCr
JOHNSON & JOHNSON	-7.15%	35TCr
MERCK & CO., INC.	+18.77%	33TCr
ABBVIE INC.	+8.79%	30TCr
ASTRAZENECA PLC	+18.02%	25TCr
ROCHE HOLDING AG	+1.27%	22TCr
NOVARTIS AG	+11.95%	22TCr
AMGEN INC.	+3.68%	16TCr

Other Pharmaceuticals